Anti-TB drug resistance in Tanga, Tanzania: A cross sectional facility-base prevalence among pulmonary TB patients
Loading...
Date
2015-11
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective: To determine the prevalence and risk factors associated with drug resistance
tuberculosis (TB) at facility-base level in Tanga, Tanzania.
Methods: A total of 79 Mycobacterium tuberculosis (MTB) isolates included in the
study were collected from among 372 (312 new and 60 previously treated) TB suspects
self-referred to four TB clinics during a prospective study conducted from November
2012 to January 2013. Culture and drug susceptibility test of the isolates was performed
at the institute of medical microbiology and epidemiology of infectious diseases, University
hospital, Leipzig, Germany. Data on the patient's characteristics were obtained
from structured questionnaire administered to the patients who gave informed verbal
consent. Unadjusted bivariate logistic regression analysis was performed to assess the risk
factors for drug resistant-TB. The significance level was determined at P < 0.05.
Results: The overall proportions of any drug resistance and MDR-TB were 12.7% and
6.3% respectively. The prevalence of any drug resistance and MDR-TB among new cases
were 11.4% and 4.3% respectively, whereas among previously treated cases was 22.2%
respectively. Previously treated patients were more likely to develop anti-TB drug
resistance. There was no association between anti-TB drug resistances (including MDRTB)
with the risk factors analysed.
Conclusions: High proportions of anti-TB drug resistance among new and previously
treated cases observed in this study suggest that, additional efforts still need to be done in
identifying individual cases at facility-base level for improved TB control programmes
and drug resistance survey should continuously be monitored in the country.
Description
Asian Pacific Journal of Tropical Medicine 2015; Vol. 8 (11) : 907-913
Keywords
Pulmonary tuberculosis, Prevalence, Drug resistance, MDR-TB, Facility-base, HIV